• Product name
    Anti-JAK2 antibody [EPR108(2)]
    See all JAK2 primary antibodies
  • Description
    Rabbit monoclonal [EPR108(2)] to JAK2
  • Host species
  • Tested applications
    Suitable for: ICC/IF, WB, IPmore details
    Unsuitable for: IHC-P
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human JAK2 aa 1100-1200 (C terminal).

  • Positive control
    • TF-1, K562, THP-1, Jurkat, NIH 3T3, Ramos, C6 and IM-9 cell lysates
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab108596 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/150.

For unpurified use at 1/100 - 1/500.

WB 1/5000. Detects a band of approximately 130 kDa (predicted molecular weight: 131 kDa).

For unpurified use at 1/1000.

IP 1/500.
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function
      Non-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight (By similarity). Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
    • Tissue specificity
      Expressed in blood, bone marrow and lymph node.
    • Involvement in disease
      Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
      Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.
      Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
      Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
      Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
      Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
      Contains 1 FERM domain.
      Contains 1 protein kinase domain.
      Contains 1 SH2 domain.
    • Domain
      Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1.
    • Post-translational
      Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity.
    • Cellular localization
      Endomembrane system. Nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • JAK 2 antibody
      • JAK-2 antibody
      • JAK2 antibody
      • JAK2_HUMAN antibody
      • Janus Activating Kinase 2 antibody
      • Janus kinase 2 (a protein tyrosine kinase) antibody
      • Janus kinase 2 antibody
      • JTK 10 antibody
      • JTK10 antibody
      • kinase Jak2 antibody
      • OTTHUMP00000043260 antibody
      • THCYT3 antibody
      • Tyrosine protein kinase JAK2 antibody
      • Tyrosine-protein kinase JAK2 antibody
      see all


    • All lanes : Anti-JAK2 antibody [EPR108(2)] (ab108596) at 1/5000 dilution (purified)

      Lane 1 : TF-1 (Human bone marrow erythroleukemia cell line) whole cell lysate
      Lane 2 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
      Lane 3 : C6 (Rat glial tumour cell line) whole cell lysate
      Lane 4 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate

      Lysates/proteins at 20 µg per lane.

      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

      Predicted band size: 131 kDa
      Observed band size: 130 kDa
      why is the actual band size different from the predicted?

      Blocking and diluting buffer and concentration: 5% NFDM/TBST.

    • Immunocytochemistry/ Immunofluorescence analysis of K562 (Human chronic myelogenous leukemia cell line from bone marrow) cells labeling JAK2 with purified ab108596 at 1/150 dilution (8.5μg/ml). Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, a goat anti-rabbit IgG(Alexa Fluor® 488) was used as the secondary antibody at 1/1000 dilution. Ab195889, anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used as the counter stain at 1/200 (2.5 μg/ml). PBS instead of the primary antibody was the negative control. DAPI was used as a nuclear counterstain.

    • All lanes : Anti-JAK2 antibody [EPR108(2)] (ab108596) at 1/1000 dilution (unpurified)

      Lane 1 : TF-1 cell lysate
      Lane 2 : K562 cell lysate
      Lane 3 : THP-1 cell lysate
      Lane 4 : Jurkat cell lysate
      Lane 5 : NIH3T3 cell lysate
      Lane 6 : IM-9 cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 131 kDa
      Observed band size: 130 kDa why is the actual band size different from the predicted?

    • Immunocytochemistry/Immunofluorescence analysis of Jurkat (Human T cell leukemia cells from peripheral blood) cells labelling JAK2 with unpurified ab108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehydeand permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).

      Confocal image showing nuclear and cytoplasmic staining on Jurkat cell line. 

    • Immunocytochemistry/Immunofluorescence analysis of Ramos (Human Burkitt's lymphoma) cells labelling JAK2 with unpurified 108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).

      Confocal image showing nuclear and cytoplasmic staining on Ramos cell line.

    • ab108596 at 1/500 dilution (3.0µg/ml) immunoprecipitating JAK2 in K562 (Human chronic myelogenous leukemia lymphoblast)  cell lysate.

      Lane 1 (input): K562(Human chronic myelogenous leukemia lymphoblast) whole cell lysate 10µg

      Lane 2 (+): K562 whole cell lysate, 350µg  + ab108596, 2µg

      Lane 3 (-): K562 cell lysate, 350µg  + rabbit IgG (ab172730), 2µg

      For western blotting, ab131366 VeriBlot for IP (HRP) was used at 1/1000.

      Blocking and dilution buffer: 5% NFDM/TBST.


    This product has been referenced in:
    • Chen Z  et al. Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. Biomed Pharmacother 109:2228-2236 (2019). Read more (PubMed: 30551480) »
    • Li W  et al. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. Oncol Rep 41:437-446 (2019). Read more (PubMed: 30365081) »
    See all 23 Publications for this product

    Customer reviews and Q&As

    Western blot
    Loading amount
    25 µg
    Gel Running Conditions
    Reduced Denaturing (4–15%)
    Mouse Tissue lysate - whole (Lung)
    Blocking step
    BSA as blocking agent for 15 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C

    Abcam user community

    Verified customer

    Submitted Jun 23 2014


    Sign up